Alkaloids found in Erythroxylum coca

Global Nicotine Gum Market Trends, Growth Opportunities, Leading Players and Outlook 2020-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 7, 2020
Tobacco, Retail, Psychoactive drugs, Smoking cessation, Tobacco, Smoking, Electronic cigarettes, Alkaloids found in Erythroxylum coca, Nicotine, Chewing gum, Juul, Safety of electronic cigarettes

The "Nicotine Gum Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nicotine Gum Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • The global nicotine gum market is currently witnessing a healthy growth.
  • How has the global nicotine gum market performed so far and how will it perform in the coming years?
  • What is the structure of the global nicotine gum market and who are the key players?

Psychemedics Test for Cotinine (metabolite of Nicotine) Detection Cleared by FDA

Retrieved on: 
Wednesday, April 29, 2020
Psychoactive drugs, Nicotinic agonists, Pyridine alkaloids, Health, Chemical compounds, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine, Food and Drug Administration, Cotinine, Psychoactive drugs, Nicotinic agonists, Pyridine alkaloids, Health, Chemical compounds, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine, Food and Drug Administration, Cotinine

Hair testing provides several significant advantages over other methods of testing including a 90-day lookback period for the ingestion of drugs.

Key Points: 
  • Hair testing provides several significant advantages over other methods of testing including a 90-day lookback period for the ingestion of drugs.
  • Psychemedics new cotinine test is an accurate and economical way to equip educators and companies alike with the capability to quickly detect people using nicotine.
  • We believe Psychemedics superior science delivers the most sensitive FDA 510(k) cleared tests in the world resulting in unmatched detection rates.
  • Psychemedics is the standard against which all others measure themselves for sensitivity, quality, and innovation to stay ahead of the ever-changing illicit drug landscape.

Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery

Retrieved on: 
Monday, January 13, 2020
Psychoactive drugs, Smoking, Chemistry, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine, Cloud computing, Computational chemistry

Computations that would otherwise have taken months to complete were achieved in five days using Oracle's high-performance cloud infrastructure.

Key Points: 
  • Computations that would otherwise have taken months to complete were achieved in five days using Oracle's high-performance cloud infrastructure.
  • The speed of results represents a breakthrough in computational chemistry and is transformational from a research perspective.
  • "By harnessing the power of cloud computing, we can quickly observe how nicotine exerts its effects at the molecular level.
  • This information can inform future drug development of new treatments for companies like Achieve."

U-Haul to Implement Nicotine-Free Hiring Policy for Healthier Workforce

Retrieved on: 
Monday, December 30, 2019
Psychoactive drugs, Electronic cigarettes, Tobacco, Smoking, Alkaloids found in Erythroxylum coca, Anxiolytics, Nicotine

The nicotine-free hiring policy will go into effect in 21 states on Feb. 1.

Key Points: 
  • The nicotine-free hiring policy will go into effect in 21 states on Feb. 1.
  • The employment of Team Members hired prior to that date will not be impacted by the policy.
  • This policy furthers the progression of U-Haul to establish one of the healthiest corporate cultures in the U.S. and Canada.
  • Individuals seeking U-Haul jobs in the aforementioned 21 states will see statements regarding the nicotine-free hiring policy on applications, and will be questioned about nicotine use.

Oyster Point Pharma Announces Positive Top-Line Results From the Phase 1 “ZEN” Study of Its Lead Nicotinic Agonist Nasal Spray in Development for the Treatment of Dry Eye Disease

Retrieved on: 
Friday, November 22, 2019
Psychoactive drugs, Branches of biology, Nicotinic antagonists, Neurochemistry, Nicotinic agonists, Stimulants, Alkaloids found in Erythroxylum coca, Anxiolytics, Nicotine, Acetylcholine receptor

The study demonstrated that OC-01 nasal spray was safe and well-tolerated at the doses tested.

Key Points: 
  • The study demonstrated that OC-01 nasal spray was safe and well-tolerated at the doses tested.
  • The most common adverse events in the nasal spray group were sneeze in 7 volunteers (33.3 percent) and cough in 6 volunteers (28.6 percent).
  • "We are pleased by the positive results of the ZEN study as they confirm and validate the pharmacokinetic profile and the fundamental science of our OC-01 nasal spray.
  • Oyster Point Pharmas lead product candidate, OC-01 nasal spray, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.

22nd Century Group Comments on Delay of Reduced Nicotine Rule for Cigarettes

Retrieved on: 
Thursday, November 21, 2019
Psychoactive drugs, Tobacco, Carcinogens, Electronic cigarettes, Nicotinic agonists, Smoking cessation, Alkaloids found in Erythroxylum coca, Anxiolytics, Nicotine, Cigarette, Modified risk tobacco product, Tobacco harm reduction

22nd Century Group is disappointed that FDA appears to have delayed its efforts to enact a product standard rule to lower the amount of nicotine in all cigarettes sold in the United States to non-addictive levels, said Cliff Fleet, CEO of 22nd Century Group.

Key Points: 
  • 22nd Century Group is disappointed that FDA appears to have delayed its efforts to enact a product standard rule to lower the amount of nicotine in all cigarettes sold in the United States to non-addictive levels, said Cliff Fleet, CEO of 22nd Century Group.
  • Furthermore, we remain optimistic about the approval of our Modified Risk Tobacco Product (MRTP) application for very-low nicotine content cigarettes.
  • FDA representatives Stephanie Caccomo and Michael Felberbaum both said the agency is reviewing comments it received in response to the proposal to cap nicotine levels in cigarettes.
  • 22nd Century continues to believe an industry-wide, national nicotine reduction mandate is the best way to reduce the harm caused by smoking, said John Pritchard, Vice President of Regulatory Science for 22nd Century Group.

CPSC Issues Warning: Liquid Nicotine Can Be Deadly for Children and Pets

Retrieved on: 
Thursday, October 24, 2019
Psychoactive drugs, Electronic cigarettes, Carcinogens, Smoking cessation, Alkaloids found in Erythroxylum coca, Anxiolytics, Nicotine, Electronic cigarette, Child-resistant packaging, Cigarette, Adverse effects of electronic cigarettes, Safety of electronic cigarettes

The U.S. Consumer Product Safety Commission (CPSC) warns consumers that even small amounts of liquid nicotine can be extremely hazardous to children and pets who swallow it or come into contact with it through their skin.

Key Points: 
  • The U.S. Consumer Product Safety Commission (CPSC) warns consumers that even small amounts of liquid nicotine can be extremely hazardous to children and pets who swallow it or come into contact with it through their skin.
  • Parents and caregivers should always store liquid nicotine in its child-resistant packaging, tightly seal the container after each use, and keep it locked up and away from children and pets.
  • When handling solutions containing liquid nicotine, adults should also be careful to minimize direct skin contact.
  • Liquid nicotine is commonly used in e-cigarettes and is available to consumers in a variety of stores and online.

New Jersey Teen Files Product Liability Lawsuit Against JUUL Manufacturer

Retrieved on: 
Tuesday, September 10, 2019
Psychoactive drugs, Nicotinic agonists, Smoking, Health effects of tobacco, Alkaloids found in Erythroxylum coca, Anxiolytics, Nicotine, Tobacco, Nausea, Adverse effects of electronic cigarettes

In just the past 18 months, he has suffered behavioral and cognitive problems, declining academic status, and was hospitalized for three days in August.

Key Points: 
  • In just the past 18 months, he has suffered behavioral and cognitive problems, declining academic status, and was hospitalized for three days in August.
  • During his hospitalization Mr. Divello battled fever, nausea, and severe vomiting, all symptoms tied to high levels of nicotine.
  • The lawsuit notes that this exposure leads to lifelong risks for heart disease, stroke, cancer and depression, as well as long-term treatment for such conditions.
  • The result was a dangerous, pervasive product that quickly met its goal of getting young people addicted to tobacco."

Governor Whitmer's Executive Ban on Vapor Products Is a Hazard to Public Health

Retrieved on: 
Wednesday, September 4, 2019
Psychoactive drugs, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine, Teratogens, Ban, Whitmer

Governor Whitmer's ban makes Michigan the first state in the nation to become a breeding ground for black market nicotine products.

Key Points: 
  • Governor Whitmer's ban makes Michigan the first state in the nation to become a breeding ground for black market nicotine products.
  • The public health effects from the rise of tainted products, organized crime, and the likely increase in smoking will end up orders of magnitude greater than what the Governor sees through blinkered eyes as the problem.
  • "Governor Whitmer is leaping to the prohibition endgame without considering the dramatic negative effect this will have on Michigan's public health.
  • If there was any policy that would make these products more risky, a flavor ban is at the top of the list.

Next Generation Labs Receives USPTO Notice of Allowance for Nicotine Replacement Therapy Patent Using Synthetic Nicotine

Retrieved on: 
Monday, August 26, 2019
Psychoactive drugs, Smoking cessation, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine, Safety of electronic cigarettes

SAN DIEGO, Aug. 25, 2019 /PRNewswire-PRWeb/ -- Next Generation Labs, the sole manufacturer of TFN nicotine, the world's only bulk synthetic nicotine not made from, or derived from tobacco, has received a Notice of Allowance from the US Patent and Trade Mark Office (USPTO) in US 2017-0189388 for methods of treating nicotine addiction using a synthetic nicotine protocol.

Key Points: 
  • SAN DIEGO, Aug. 25, 2019 /PRNewswire-PRWeb/ -- Next Generation Labs, the sole manufacturer of TFN nicotine, the world's only bulk synthetic nicotine not made from, or derived from tobacco, has received a Notice of Allowance from the US Patent and Trade Mark Office (USPTO) in US 2017-0189388 for methods of treating nicotine addiction using a synthetic nicotine protocol.
  • The patent application, titled "Nicotine replacement therapy products comprising synthetic nicotine," specifically claims a method for administration of a first ratio of synthetic R and S nicotine, and a subsequent administration of a second and different ratio of synthetic R and S nicotine.
  • The synthetic nicotine used in the administrations includes a "nicotine product comprising a synthetic nicotine substantially free of one or more of nicotine-1-N-oxide, nicotyrine, nornicotyrine, cotinine, 2,3-bipyridyl, anabasine, N-methyl anatabine, N-methyl anabasine, anabasine, and/or anatabine."
  • Next Generation Labs is pleased this patent application has been allowed, as it helps establish the potential for use of the R and S isomers of synthetic nicotine in future nicotine replacement and smoking cessation products.